
Aims: Lipoprotein(a) (Lp(a)) is a strong risk factor for cardiovascular events, independent of low-density lipoprotein cholesterol (LDL-C). Because the Lp(a) concentration is largely determined by genetic factors, some dyslipidemia guidelines recommend a once-in-a-lifetime measurement of Lp(a). Furthermore, a non-fasting lipid profile assessment is allowed for initial screening of dyslipidemia. Although the LDL-C concentration decreases slightly throughout the day, the within-day variation of Lp(a) remains unknown. We aimed to investigate whether the Lp(a) concentration remains stable throughout the day. Methods: Lp(a) concentrations were measured at seven time points throughout the day in 34 patients using a latex turbidimetric immunoassay. The Lp(a) values are expressed in molar units, which are equivalent to those determined by a mass spectrometry-based reference measurement procedure. Results: We found that the Lp(a) concentrations decreased by 2.9 +/- 5.2 nmol/L at 14:00 (p<0.05), 3.6 +/- 4.8 nmol/L at 20:00 (p<0.001), and 2.9 +/- 5.1 nmol/L at 24:00 (p<0.05). The mean percent Lp(a) decreased significantly at 17:30 (-6.2 +/- 0.1%) and 24:00 (-7.0 +/- 0.1%) from the fasting level. Conclusion: The Lp(a) concentration decreases slightly, but significantly, throughout the day. Considering physiological variations, it is preferable to re-evaluate the Lp(a) concentration in those with a borderline elevation.
Aims: The stiffness parameter 13 is a clinical index of arterial stiffness that reflects systemic atherosclerosis. Chronic kidney disease (CKD) is a major cardiovascular risk factor in type 2 diabetes; however, it remains unclear whether a reduced kidney function or albuminuria is more strongly associated with arterial stiffness. This study examined the relative associations of estimated glomerular filtration rate (eGFR) and urinary albumin-tocreatinine ratio (UACR) with stiffness parameter 13 in patients with type 2 diabetes. Methods: This cross-sectional study enrolled 1,924 patients with type 2 diabetes. The stiffness parameter 13 was assessed at the common carotid artery using ultrasonography. Results: The participants were 58.8% male, with a median age of 63 years and a median HbA1c level of 8.3%. According to univariate analyses, stiffness parameter 13 was significantly correlated with both eGFR and UACR. However, after adjusting for conventional cardiovascular risk factors, stiffness parameter 13 remained independently associated with UACR, whereas no independent association was observed with eGFR. Similar findings were observed when eGFR and albuminuria were analyzed according to the CKD categories. No significant interactions were observed between UACR and either age or body mass index in relation to stiffness parameter 13. Conclusions: In patients with type 2 diabetes, albuminuria, but not eGFR, was independently associated with stiffness parameter 13 after multivariable adjustment. These findings suggest that albuminuria may serve as a marker of local carotid arterial stiffening and vascular injury.